Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Oct;61(10):849-53.
doi: 10.1136/thx.2006.059808. Epub 2006 May 31.

C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease

Affiliations

C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease

S F P Man et al. Thorax. 2006 Oct.

Abstract

Background: Although C-reactive protein (CRP) levels are increased in chronic obstructive pulmonary disease (COPD), it is not certain whether they are associated with adverse clinical outcomes.

Methods: Serum CRP levels were measured in 4803 participants in the Lung Health Study with mild to moderate COPD. The risk of all-cause and disease specific causes of mortality was determined as well as cardiovascular event rates, adjusting for important covariates such as age, sex, cigarette smoking, and lung function. Cardiovascular events were defined as death from coronary heart disease or stroke, or non-fatal myocardial infarction or stroke requiring admission to hospital.

Results: CRP levels were associated with all-cause, cardiovascular, and cancer specific causes of mortality. Individuals in the highest quintile of CRP had a relative risk (RR) for all-cause mortality of 1.79 (95% confidence interval (CI) 1.25 to 2.56) compared with those in the lowest quintile of CRP. For cardiovascular events and cancer deaths the corresponding RRs were 1.51 (95% CI 1.20 to 1.90) and 1.85 (95% CI 1.10 to 3.13), respectively. CRP levels were also associated with an accelerated decline in forced expiratory volume in 1 second (p < 0.001). The discriminative property of CRP was greatest during the first year of measurement and decayed over time. Comparing the highest and lowest CRP quintiles, the RR was 4.03 (95% CI 1.23 to 13.21) for 1 year mortality, 3.30 (95% CI 1.38 to 7.86) for 2 year mortality, and 1.82 (95% CI 1.22 to 2.68) for > or =5 year mortality.

Conclusions: CRP measurements provide incremental prognostic information beyond that achieved by traditional markers of prognosis in patients with mild to moderate COPD, and may enable more accurate detection of patients at a high risk of mortality.

PubMed Disclaimer

Conflict of interest statement

Competing interests: DDS, SFM, and RW have received research funding from GlaxoSmithKline (GSK) and have received honoraria for speaking engagements from GSK and AstraZeneca.

Similar articles

Cited by

References

    1. Pauwels R A, Buist A S, Calverley P M.et al Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 20011631256–1276. - PubMed
    1. Murray C J, Lopez A D. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 19973491498–1504. - PubMed
    1. Andreassen H, Vestbo J. Chronic obstructive pulmonary disease as a systemic disease: an epidemiological perspective. Eur Respir J 200346(Suppl)2–4s. - PubMed
    1. Gan W Q, Man S F, Senthilselvan A.et al Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta‐analysis. Thorax 200459574–580. - PMC - PubMed
    1. Wouters E F. Chronic obstructive pulmonary disease – 5: Systemic effects of COPD. Thorax 2002571067–1070. - PMC - PubMed

Publication types

Substances

-